NCT07834268Active, not recruiting
Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS)
NQMD-CS: A Prospective Interventional Study to Evaluate the Feasibility of a Blood-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
This is a prospective, multicenter screening cohort study designed to evaluate the feasibility of a blood-based multi-cancer early detection (MCED) test in an asymptomatic screening population. Eligible participants will undergo blood-based MCED testing, standard cancer screening as appropriate, and 1-year active follow-up. Participants with positive MCED results or highly suspicious findings from standard screening will undergo diagnostic evaluation to determine cancer status, enabling a more accurate assessment of the test's clinical performance.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 1250 (actual)
- First submitted
- 16 Sept 2026
- Start date
- 2 Jul 2025
- Primary completion date
- Oct 2026
- Lead sponsor
- Fifth Affiliated Hospital of Guangzhou Medical University
- Diseases
- Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT07834268
What you commit to
- Study type: Interventional
- Participants enrolled: 1250
- From 2 Jul 2025 to the primary completion date, Oct 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen;
- Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrine therapy for cancer is not an exclusion criterion;
- Recipients of anti-tumor therapy within 30 days prior to screen;
- Recipients of organ transplant or prior bone marrow transplant or stem cell transplant;
- Recipients of blood transfusion within 7 days prior to screen;
- Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw;
Other illness
- Have definite contraindications of cancer screening examination and diagnostic procedures;
- Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date;
- With autoimmune diseases;
Other
- Unable to comply with the protocol procedures;
- Pregnancy or lactating women;
- Unsuitable for this trial determined by the researchers.
Who the study is looking for
- 1.40-74 years old; 2.Able to provide a written informed consent; 3.Willing to comply with all part of the protocol procedures.
Age in the registry: 40 years to 74 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fifth Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Huidong People's Hospital Coordinator of this site? Confirm its status | Huizhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.